Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses Toe Tourniquet Syndrome, a frequently misdiagnosed condition that can lead to necrosis if untreated, and calls for increased clinician awareness, but reports no new clinical findings.

CTP-543 is generally safe for treating alopecia areata.

In this study, researchers found that Compound Baqian Danshen Liniment may improve vitiligo in mice by promoting melanocyte activity and reducing inflammation and oxidative stress.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This study found that topical tacalcitol improved roughness and scaling in erythromelanosis follicularis faciei et colli, although it was less effective for facial erythema.

This report suggests a possible association between temporal triangular alopecia and sebaceous nevus, and identifies a pinkish background as a new trichoscopic finding for TTA.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

Tofacitinib might be used to treat hair loss.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This comprehensive review reports that Thuja orientalis L. displays several pharmacological properties, including antimicrobial, anti-inflammatory, antioxidant, anticarcinogenic, anthelminthic, and hair growth-promoting effects, emphasizing its potential in modern medicine and the need for further research.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

QMSI effectively maps and quantifies drug distribution in skin tissues.

In this study, the researchers explored the traditional Chinese medicine approach to treating seborrheic alopecia, emphasizing the interplay between zang-fu organs, qi, blood, and body fluids, and highlighted treatments focusing on wind, dampness, heat, blood stasis, and deficiency.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

This study reports the development of a novel protocol to purify human TRPV3 ion channels, revealing functional properties and differences in ligand interactions, enabling further structural and functional research.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

In this case report, a 14-year-old male with alopecia areata subtotalis and nail involvement showed significant improvement after 9 months of treatment with oral tofacitinib, including complete hair regrowth and nail texture improvement, though further studies are needed to confirm these findings.

In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.